吗替麦考酚酯与来氟米特治疗难治性肾病综合征的

A comparative study of mycophenolate mofetil versus leflunomide in the treatment with refractory nephropathy syndrome

目的:探讨吗替麦考酚酯(MMF)与来氟米特治疗难治性肾脏综合征的疗效及安全性。方法:分别以吗替麦考酚酯与来氟米特治疗难治性肾病综合征均32例,随机分为治疗组和对照组。两组患者均采用强的松(起始剂量0.8mg/kg.d-1)治疗的基础上。在治疗前及治疗后第2、4、6、8、10及12周动态监测各项临床指标。比较12周的疗效及安全性。结果:MMF组24h尿蛋白较治疗前明显下降,血浆白蛋白在治疗后明显升高,完全缓解率为53.1%,总有效率78.1%。对照组24h尿蛋白与治疗组无差异性,完全缓解率为50%,总有效率71.9%,两组疗效相当。治疗组不良反应发生率均低于对照组。结论:吗替麦考酚酯治疗难治性肾病综合征的近期疗效较好,且不良反应少,耐受性好。

Objective To compare the efficecy and side effects of mycophenolate mofetil (MMF) and leflunomide therapy in the treatment of refractory nephropathy syndrome.Methods Thirty two Refractory nephropathy syndrome patients were treated With mycophenolate mofetil and another thirty two patient treated with leflumomide, They were divided into MMF or leflunomide. All patients received Prednisone. Clinical data were observed in the 2nd、4th、6th、8th、10th and 12th week. The clinical and pathological parameters were compared between The two groups. Results After receiving mycophenolate mofetil theraphy, the proteinuric was decreased significanly (P<0.01);serum albumin was increased significantly (P<0.01); complete relieving rat was 53.1%. and total effective rat was 78.1%. The officacy rate of leflumomide was 50%. in which 71.9%. There was no significant in the efficact beween mycophenolatemofetil and leflumomide.the side effects of mycophenolate mofetil were lower than those of leflumomide .Conclusion mycophenolate mofetil is a safe and effective medicine in treatment refractory nephropathy syndrome